InspireMD Inc Dossier
Qualitative Analysis
Business overview
InspireMD, Inc. (Nasdaq: NSPR) is a commercial-stage medical device company focused on the development and commercialization of proprietary carotid stent systems designed for stroke prevention. The company's core technology is its proprietary MicroNet™ mesh, a biocompatible polymer material that wraps around a self-expanding nitinol stent. This dual-layer architecture is designed to prevent plaque protrusion and capture debris that could otherwise dislodge and travel to the brain during and after carotid interventions. Its flagship product family includes the CGuardu0000 Carotid Embolic Prevention System (EPS) and the next-generation CGuardu0000 Prime. InspireMD serves hospitals and vascular specialists performing carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR) procedures globally.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Voluntarily pausing the U.S. commercialization of the CGuard Prime 135 cm delivery system to implement design enhancements, while preparing to re-enter the U.S. market with the original CGuard delivery system.
Expected impact: Resolves technical performance issues identified during the controlled launch and establishes a more robust delivery platform for long-term U.S. market penetration.
Advancing the CGuard Prime 80 cm delivery system and the SwitchGuard neuroprotection system for transcarotid artery revascularization (TCAR) procedures.
Expected impact: Doubles the addressable U.S. market opportunity and allows InspireMD to offer a complete, proprietary TCAR toolkit.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to conduct the CGUARDIANS II pivotal study of the CGuard Prime 80 cm carotid stent system for use in TCAR procedures.
Terms: Not disclosed